Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symbiotic-GI-13: PF-08634404 in Unresectable or Metastatic Hepatocellular Carcinoma
2025-523525-17-00Phase 2Authorised
- Sponsor
- Pfizer
- Start
- Apr 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, open-label trial of PF-08634404 in hepatocellular carcinoma (HCC) (2 arms), sponsored by Pfizer. Primary endpoints: Adverse events (Phase 1b safety run-in), Dose-limiting toxicities (DLTs) and 2 more. Planned start Apr 2026; status: authorised.
02
Drugs
PF-08634404
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2025-523525-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523525-17-00.